Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal LINQ In-Office 2 (RIO 2) Study. One of the world's smallest cardiac monitors, the Reveal LINQ insertable cardiac monitor (ICM) was successfully implanted in an office setting at Scripps Clinic in La Jolla, California, by cardiologist John Rogers, M.D. The RIO 2 study will determine if the procedure, performed in an in-office setting, is as safe as procedures performed in a traditional hospital setting — such as an operating room, cardiac catheterization laboratory or electrophysiology laboratory.

Medtronic plc announced that its Protege GPS self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of stenotic lesions of the common and external iliac arteries.

Vital Images Inc. will debut its U.S. Food and Drug Administration (FDA) 510(k)-cleared CT Myocardial Perfusion application at the 10th annual scientific meeting of the Society of Cardiovascular Computed Tomography (SCCT). The meeting will be held in Las Vegas July 16-19.

Infinitt announced today that it has entered into a seven-year Partner Plus Agreement with TridentUSA Health Services based on an unlimited software licensing model for Infinitt PACS and Cardiology Suite, in addition to custom software development. The contract also encompasses Infinitt's embedded voice recognition and reporting software, as well as the new Gx Communicator package (Critical Results, Peer Review and Collaborator Instant Messaging).

Konica Minolta Medical Imaging announced new Blue Moon Lifecycle Solutions designed to help customers minimize downtime, maximize productivity, and eliminate risk for the lifetime of their handheld Sonimage P3 and portable Sonimage HS1 ultrasound systems. The company will introduce the new Blue Moon Lifecycle Solutions at the Association for Medical Imaging Management (AHRA) annual meeting, July 20-22 in Las Vegas.


Thoratec announced that the HeartMate PHP (Percutaneous Heart Pump) received CE Mark approval, permitting sale in the European Union and other international countries. Approval was based on data from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark Trial examining use of PHP to support patients undergoing a high-risk percutaneous coronary intervention (PCI) procedure. Data from all 50 patients enrolled in this study will be presented later in 2015.


Subscribe Now